The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

ESMO 2025
Presentations Supported by Bayer
October 17-21, 2025

Agenda of oral and poster presentations at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.

Please select a compound to navigate to all related publications.

 

 

 

    ALL

    DAROLUTAMIDE

    Darolutamide efficacy, quality of life, and safety outcomes by age subgroup: ARANOTE post hoc analyses
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Fred Saad
    Presentation #:
    2459P
    Download the poster View the video
    Real-world experience with darolutamide in 799 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): prespecified interim analysis of the DAROL prospective observational study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Murilo De Almeida Luz
    Presentation #:
    2458P
    Download the poster View the video
    Patient perspectives of symptom burden and impact of hormone therapy (HT) in the USA and Germany
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Gunhild Von Amsberg
    Presentation #:
    2447P
    Download the poster View the video
    Real-world prostate-specific antigen (PSA) response with darolutamide or abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) triplet therapy
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Alicia K. Morgans
    Presentation #:
    2477P
    Download the poster View the video
    Estimating Median Overall Survival (OS) to inform the ESMO-MCBS scores in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) using ARAMIS study
    Date/Time:
    October 18, 2025
    Session:
    Prostate cancer
    Type:
    E-poster
    Presenting Author:
    Martin Boegemann
    Presentation #:
    2522eP
    Download the poster View the video
    LBA92: 3-weekly docetaxel 75 mg/m2 vs. 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC – results from the randomised, phase 3 ARASAFE trial
    Date/Time:
    October 17, 2025 | 14:10-14:15 CEST
    Session:
    Mini oral session: GU tumours, prostate, penile and testis
    Type:
    Mini Oral Session
    Presenting Author:
    Marc-Oliver Grimm
    Presentation #:
    LBA92
    Download the presentation
    Neoadjuvant darolutamide plus ADT for High/Very-high risk locally advanced PCa: a multi-center, open label, single arm, phase 2 trial
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Kaiwei Yang
    Presentation #:
    2476P
    Download the poster
    A randomized, multicenter, phase II trial of docetaxel or cabazitaxel with or without darolutamide in patients with metastatic castration-resistant prostate cancer (the DAROTAXEL study)
    Date/Time:
    October 18, 2025
    Session:
    Prostate cancer
    Type:
    ePoster
    Presenting Author:
    Tanja C. Van Dijk
    Presentation #:
    2541eTiP
    Download the poster
    Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer (CRPC) and oligometastases on functional imaging (GETUG-AFU 43–PEACE8)
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Ronan Flippot
    Presentation #:
    2517TiP
    Download the poster

    LAROTRECTINIB

    Real-world study of larotrectinib in patients with TRK fusion solid tumours: Interim analysis of ON-TRK
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Developmental therapeutics
    Type:
    Poster
    Presenting Author:
    Jonathan C. Trent
    Presentation #:
    969P
    Download the poster
    Efficacy and safety of larotrectinib in patients with TRK fusion cancer who achieved complete response
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Developmental therapeutics
    Type:
    Poster
    Presenting Author:
    Noah Federman
    Presentation #:
    970P
    Download the poster
    Efficacy and safety of larotrectinib in patients with TRK fusion cancer who had a long-term response
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Developmental therapeutics
    Type:
    Poster
    Presenting Author:
    David S. Hong
    Presentation #:
    971P
    Download the poster View the video
    Long-term efficacy and safety of larotrectinib in TRK fusion primary central nervous system tumours: an updated analysis
    Date/Time:
    Monday, October 20, 2025 | 9:10 AM – 9:15 AM CEST
    Session:
    Mini Oral session: CNS tumours
    Type:
    Mini Oral Session
    Presenting Author:
    Lorena Valero-Arrese
    Presentation #:
    664MO
    Download the presentation

    RADIUM-223

    A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): first analysis of the AlphaBet trial
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Louise Kostos
    Presentation #:
    2386P
    Download the poster
    Bone Fractures and Prior Abiraterone Use in Men Treated with Radium-223 and Enzalutamide Combination for Castration Resistant Prostate Cancer (CRPC) with Bone Metastases(m): A Real-World Observational Study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Rana R. McKay 
    Presentation #:
    2414P
    Download the poster
    Combined treatment with radium-223 (RAD) and enzalutamide (ENZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): insights from the global REASSURE study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Igle Jan de Jong 
    Presentation #:
    2401P
    Download the poster

    REGORAFENIB

    Regorafenib plus Irinotecan versus regorafenib alone in metastatic colorectal cancer after standard therapies failure in cyclin D1 A/A(870) genotype patients : the randomized phase III NEXT-REGIRI trial
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Colorectal cancer
    Type:
    Poster
    Presenting Author:
    Emmanuelle Samalin-Scalzi 
    Presentation Number #:
    747P
    Download the poster
    A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: the REGOMA-2 trial
    Date/Time:
    October 20, 2025 | 8:30 - 8:35 CEST
    Session:
    Mini Oral Session: CNS tumours
    Type:
    Mini Oral
    Presenting Author:
    Giuseppe Lombardi
    Presentation Number #:
    660MO
    Download the presentation
    Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma after first-line therapy (GOING trial)
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Hepatocellular carcinoma (HCC)
    Type:
    Poster
    Presenting Author:
    Maria Elisa Reig Monzon
    Presentation Number #:
    1501P
    Download the poster
    A phase 2 clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel)
    Date/Time:
    October 20, 2025 | 12:00-12:45 CEST
    Session:
    Melanoma and other skin tumours
    Type:
    Poster
    Presenting Author:
    Iris Dirven 
    Presentation Number #:
    1643P
    Download the poster
    Evaluation of the benefit-risk ratio in EREMISS randomized trial using Q-TWiST and GPC methods
    Date/Time:
    October 20, 2025 | 12:00-12:45 CEST
    Session:
    Sarcoma
    Type:
    Poster
    Presenting Author:
    Benjamin Verret 
    Presentation Number #:
    2698P
    Download the poster
    Interim analysis of the REFINE-IO study of systemic therapies in patients (pts) with unresectable hepatocellular carcinoma (uHCC) following first-line (1L) immune checkpoint inhibitor (ICI) combination therapy
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Hepatocellular carcinoma (HCC)
    Type:
    Poster
    Presenting Author:
    Mohamed Bouattour
    Presentation Number #:
    1499P
    Download the poster
    LBA80 - Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
    Date/Time:
    October 17, 2025 | 14:50-15:00 CEST
    Session:
    Proffered Paper Session 1: GI tumours, upper digestive
    Type:
    Proffered Paper
    Presenting Author:
    David Goldstein
    Presentation Number #:
    LBA80
    Download the presentation

    SEVABERTINIB

    LBA75: Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study
    Date/Time:
    October 17, 2025 | 16:22-16:32 CEST
    Session:
    Proffered paper session: NSCLC metastatic
    Type:
    Proffered Paper
    Presenting Author:
    Xiuning Le
    Presentation Number #:
    LBA75
    View the abstract
    Molecular factors and ctDNA dynamics associated with clinical outcomes in patients with HER2-Mutant NSCLC treated with sevabertinib (BAY 2927088): Exploratory analysis of the SOHO-01 Study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    NSCLC, metastatic
    Type:
    Poster
    Presenting Author:
    Nicolas Girard
    Presentation Number #:
    2001P
    View the abstract
    DAROLUTAMIDE

    DAROLUTAMIDE

    Darolutamide efficacy, quality of life, and safety outcomes by age subgroup: ARANOTE post hoc analyses
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Fred Saad
    Presentation #:
    2459P
    Download the poster View the video
    Real-world experience with darolutamide in 799 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): prespecified interim analysis of the DAROL prospective observational study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Murilo De Almeida Luz
    Presentation #:
    2458P
    Download the poster View the video
    Patient perspectives of symptom burden and impact of hormone therapy (HT) in the USA and Germany
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Gunhild Von Amsberg
    Presentation #:
    2447P
    Download the poster View the video
    Real-world prostate-specific antigen (PSA) response with darolutamide or abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) triplet therapy
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Alicia K. Morgans
    Presentation #:
    2477P
    Download the poster View the video
    Estimating Median Overall Survival (OS) to inform the ESMO-MCBS scores in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) using ARAMIS study
    Date/Time:
    October 18, 2025
    Session:
    Prostate cancer
    Type:
    E-poster
    Presenting Author:
    Martin Boegemann
    Presentation #:
    2522eP
    Download the poster View the video
    LBA92: 3-weekly docetaxel 75 mg/m2 vs. 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC – results from the randomised, phase 3 ARASAFE trial
    Date/Time:
    October 17, 2025 | 14:10-14:15 CEST
    Session:
    Mini oral session: GU tumours, prostate, penile and testis
    Type:
    Mini Oral Session
    Presenting Author:
    Marc-Oliver Grimm
    Presentation #:
    LBA92
    Download the presentation
    Neoadjuvant darolutamide plus ADT for High/Very-high risk locally advanced PCa: a multi-center, open label, single arm, phase 2 trial
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Kaiwei Yang
    Presentation #:
    2476P
    Download the poster
    A randomized, multicenter, phase II trial of docetaxel or cabazitaxel with or without darolutamide in patients with metastatic castration-resistant prostate cancer (the DAROTAXEL study)
    Date/Time:
    October 18, 2025
    Session:
    Prostate cancer
    Type:
    ePoster
    Presenting Author:
    Tanja C. Van Dijk
    Presentation #:
    2541eTiP
    Download the poster
    Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer (CRPC) and oligometastases on functional imaging (GETUG-AFU 43–PEACE8)
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Ronan Flippot
    Presentation #:
    2517TiP
    Download the poster
    LAROTRECTINIB

    LAROTRECTINIB

    Real-world study of larotrectinib in patients with TRK fusion solid tumours: Interim analysis of ON-TRK
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Developmental therapeutics
    Type:
    Poster
    Presenting Author:
    Jonathan C. Trent
    Presentation #:
    969P
    Download the poster
    Efficacy and safety of larotrectinib in patients with TRK fusion cancer who achieved complete response
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Developmental therapeutics
    Type:
    Poster
    Presenting Author:
    Noah Federman
    Presentation #:
    970P
    Download the poster
    Efficacy and safety of larotrectinib in patients with TRK fusion cancer who had a long-term response
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Developmental therapeutics
    Type:
    Poster
    Presenting Author:
    David S. Hong
    Presentation #:
    971P
    Download the poster View the video
    Long-term efficacy and safety of larotrectinib in TRK fusion primary central nervous system tumours: an updated analysis
    Date/Time:
    Monday, October 20, 2025 | 9:10 AM – 9:15 AM CEST
    Session:
    Mini Oral session: CNS tumours
    Type:
    Mini Oral Session
    Presenting Author:
    Lorena Valero-Arrese
    Presentation #:
    664MO
    Download the presentation
    RADIUM-223

    RADIUM-223

    A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): first analysis of the AlphaBet trial
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Louise Kostos
    Presentation #:
    2386P
    Download the poster
    Bone Fractures and Prior Abiraterone Use in Men Treated with Radium-223 and Enzalutamide Combination for Castration Resistant Prostate Cancer (CRPC) with Bone Metastases(m): A Real-World Observational Study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Rana R. McKay 
    Presentation #:
    2414P
    Download the poster
    Combined treatment with radium-223 (RAD) and enzalutamide (ENZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): insights from the global REASSURE study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    Prostate cancer
    Type:
    Poster
    Presenting Author:
    Igle Jan de Jong 
    Presentation #:
    2401P
    Download the poster
    REGORAFENIB

    REGORAFENIB

    Regorafenib plus Irinotecan versus regorafenib alone in metastatic colorectal cancer after standard therapies failure in cyclin D1 A/A(870) genotype patients : the randomized phase III NEXT-REGIRI trial
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Colorectal cancer
    Type:
    Poster
    Presenting Author:
    Emmanuelle Samalin-Scalzi 
    Presentation Number #:
    747P
    Download the poster
    A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: the REGOMA-2 trial
    Date/Time:
    October 20, 2025 | 8:30 - 8:35 CEST
    Session:
    Mini Oral Session: CNS tumours
    Type:
    Mini Oral
    Presenting Author:
    Giuseppe Lombardi
    Presentation Number #:
    660MO
    Download the presentation
    Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma after first-line therapy (GOING trial)
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Hepatocellular carcinoma (HCC)
    Type:
    Poster
    Presenting Author:
    Maria Elisa Reig Monzon
    Presentation Number #:
    1501P
    Download the poster
    A phase 2 clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel)
    Date/Time:
    October 20, 2025 | 12:00-12:45 CEST
    Session:
    Melanoma and other skin tumours
    Type:
    Poster
    Presenting Author:
    Iris Dirven 
    Presentation Number #:
    1643P
    Download the poster
    Evaluation of the benefit-risk ratio in EREMISS randomized trial using Q-TWiST and GPC methods
    Date/Time:
    October 20, 2025 | 12:00-12:45 CEST
    Session:
    Sarcoma
    Type:
    Poster
    Presenting Author:
    Benjamin Verret 
    Presentation Number #:
    2698P
    Download the poster
    Interim analysis of the REFINE-IO study of systemic therapies in patients (pts) with unresectable hepatocellular carcinoma (uHCC) following first-line (1L) immune checkpoint inhibitor (ICI) combination therapy
    Date/Time:
    October 19, 2025 | 12:00-12:45 CEST
    Session:
    Hepatocellular carcinoma (HCC)
    Type:
    Poster
    Presenting Author:
    Mohamed Bouattour
    Presentation Number #:
    1499P
    Download the poster
    LBA80 - Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
    Date/Time:
    October 17, 2025 | 14:50-15:00 CEST
    Session:
    Proffered Paper Session 1: GI tumours, upper digestive
    Type:
    Proffered Paper
    Presenting Author:
    David Goldstein
    Presentation Number #:
    LBA80
    Download the presentation
    SEVABERTINIB

    SEVABERTINIB

    LBA75: Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study
    Date/Time:
    October 17, 2025 | 16:22-16:32 CEST
    Session:
    Proffered paper session: NSCLC metastatic
    Type:
    Proffered Paper
    Presenting Author:
    Xiuning Le
    Presentation Number #:
    LBA75
    View the abstract
    Molecular factors and ctDNA dynamics associated with clinical outcomes in patients with HER2-Mutant NSCLC treated with sevabertinib (BAY 2927088): Exploratory analysis of the SOHO-01 Study
    Date/Time:
    October 18, 2025 | 12:00-12:45 CEST
    Session:
    NSCLC, metastatic
    Type:
    Poster
    Presenting Author:
    Nicolas Girard
    Presentation Number #:
    2001P
    View the abstract

     

    The compendium provided by Bayer is a compilation of Presentations Sponsored by Bayer & Presentations from Bayer-supported Investigator-Initiated Research. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The European Society for Medical Oncology (ESMO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
    Reused with permission. © 2025 European Society for Medical Oncology (ESMO). All rights reserved.
    For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR
    © 2025 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 10/25

    MA-M_DAR-US-0376-1

    The compendium provided by Bayer is a compilation of Presentations Sponsored by Bayer & Presentations from Bayer-supported Investigator-Initiated Research. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The European Society for Medical Oncology (ESMO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
    Reused with permission. © 2025 European Society for Medical Oncology (ESMO). All rights reserved.
    For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR
    © 2025 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 10/25

    MA-M_DAR-US-0377

    © 2023 Bayer. All rights reserved.
    Bayer and the Bayer Cross are registered trademarks of Bayer.
    MA-M_DAR-US-0203-1
    3/23

    © 2023 Bayer. All rights reserved.
    Bayer and the Bayer Cross are registered trademarks of Bayer.
    MA-M_DAR-US-0204-1
    3/23